<DOC>
	<DOCNO>NCT00969917</DOCNO>
	<brief_summary>The primary objective study determine safety profile overall response rate IPI 504 patient advance dedifferentiated liposarcoma .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety IPI 504 Patients With Advanced Dedifferentiated Liposarcoma</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>At least 18 year age time sign informed consent . Histologic diagnosis dedifferentiate liposarcoma . Available archival pathology specimen tissue sample new biopsy confirmation diagnosis central pathology reading . At least one prior chemotherapy regimen dedifferentiate liposarcoma . No 2 prior chemotherapy regimen dedifferentiate liposarcoma . Note : Any number nonchemotherapy regimen permit . Measurable disease compute tomography ( CT ) magnetic resonance imaging ( MRI ) define RECIST ( version 1.1 ) least one measurable lesion . Eastern Cooperative Oncology Group ( ECOG ) performance status : 0 1 . Life expectancy â‰¥6 month . Prior treatment heat shock protein 90 ( Hsp90 ) inhibitor . Surgery , radiotherapy , lesion ablative procedure area measurable disease Patients prior hepatic resection hepaticdirected therapy Use medication food clinically relevant CYP3A inhibitor inducer within 2 week prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>